24/7 Market News Snapshot 04 June, 2025 – Trevi Therapeutics, Inc. Common Stock (NASDAQ:TRVI)

June 4, 2025

DENVER, Colo., 04 June, 2025 (www.247marketnews.com) – (NASDAQ:TRVI) are discussed in this article.
Trevi Therapeutics, Inc. has shown remarkable market activity today with its stock price rising by approximately 9.75% to trade at $6.53, following a previous close of $5.95. This surge comes with a trading volume of 9.05 million shares, reflecting heightened investor interest. The current upward momentum highlights potential for continued growth, with key resistance identified above $6.53 and support located around $6.20. Market observers are encouraged to monitor these levels closely as they may indicate future price developments for the stock.

In a significant move, Trevi Therapeutics has also announced the successful pricing of a public offering of 17,400,000 shares of its common stock at $5.75 per share, anticipated to raise roughly $100 million before underwriting discounts and other expenses. This initiative is aimed at financing the ongoing clinical development of Haduvio™ (oral nalbuphine ER), which targets chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Notably, the underwriters have an option to purchase an additional 2,610,000 shares, which could further increase capital influx.

The offering is scheduled to close around June 5, 2025, subject to customary conditions, with reputable firms such as Morgan Stanley and Leerink Partners serving as joint book-running managers. This public offering is conducted under a registration statement that was filed with the Securities and Exchange Commission and became effective in August 2023.

Trevi remains dedicated to addressing significant unmet needs in respiratory health, leveraging Haduvio’s innovative mechanisms to enhance patient quality of life. The anticipated proceeds from this offering are intended to bolster their clinical programs and support the pathway toward potential commercialization of Haduvio, reinforcing the company’s standing in the biopharmaceutical landscape.

Related news for (TRVI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.